Dosing & Uses
Dosage Forms & Strengths
tablet
- 5mg
- 10mg
suppository
- 25mg
injectable solution
- 5mg/mL
Severe Nausea & Vomiting
PO: Immediate-release, 5-10 mg q6-8hr; extended-release, 10 mg q12hr or 15 mg every morning
Suppository: 25 mg q12hr
IM: 5-10 mg q3-4hr; not to exceed 40 mg/day
IV: 2.5-10 mg q3-4hr; not to exceed 10 mg/dose or 40 mg/day
Severe Intraoperative Nausea & Vomiting
Prophylaxis
IM: 5-10 mg administered 1-2 hours before induction of anesthesia; may be repeated once 30 minutes after initial dose
IV: 5-10 mg administered 15-30 minutes before induction of anesthesia, repeated once before procedure if desired, or 20 mg/L administered 15-30 minutes before induction; not to exceed 30 mg/day
Psychosis
5-10 mg PO q6-8hr; slowly titrate dose q2-3days; not to exceed 150 mg/day
10-20 mg IM q2-4hr to gain control; 3-4 doses rarely needed
Dosage Forms & Strengths
tablet
- 5mg
- 10mg
suppository
- 2.5mg
- 5mg
- 25mg
injectable solution
- 5mg/mL
Psychotic Disorder
<2 years: Not recommended
2-6 years: 2.5 mg PO/PR q8-12hr initially; not to exceed 20 mg/day; not to exceed 10 mg on the first day
6-12 years: 2.5 mg PO/PR q8-12hr initially; not to exceed 25 mg/day; not to exceed 10 mg on the first day
Severe Nausea & Vomiting
<2 years: Not recommended
≥2 years (9-13 kg): 2.5 mg PO daily or q12hr; not to exceed 7.5 mg/day
≥2 years (13.1-18 kg): 2.5 mg PO q8-12hr; not to exceed 10 mg/day
≥2 years (18.1-37 kg): 2.5 mg PO q8hr or 5 mg PO q12hr; not to exceed 15 mg/day
Not drug of choice in elderly, because of extrapyramidal symptoms
Nonpsychotic Dementia Behavior (Off-label)
Lower initial dose and adjust gradually; 2.5-5 mg/day PO; dosing interval may be increased to q8-12hr PRN; not to exceed 75 mg/day
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (10)
- amisulpride
amisulpride, prochlorperazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- disopyramide
prochlorperazine and disopyramide both increase QTc interval. Contraindicated.
- ibutilide
prochlorperazine and ibutilide both increase QTc interval. Contraindicated.
- indapamide
prochlorperazine and indapamide both increase QTc interval. Contraindicated.
- metrizamide
prochlorperazine, metrizamide. Mechanism: unknown. Contraindicated. Risk of seizure. D/C phenothiazine 24h before admin. of metrizamide.
- pentamidine
prochlorperazine and pentamidine both increase QTc interval. Contraindicated.
- pimozide
prochlorperazine and pimozide both increase QTc interval. Contraindicated.
- procainamide
prochlorperazine and procainamide both increase QTc interval. Contraindicated.
- quinidine
prochlorperazine and quinidine both increase QTc interval. Contraindicated.
- sotalol
prochlorperazine and sotalol both increase QTc interval. Contraindicated.
Serious - Use Alternative (68)
- aminolevulinic acid oral
aminolevulinic acid oral, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.
- aminolevulinic acid topical
prochlorperazine increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.
- amiodarone
prochlorperazine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.
- apomorphine
prochlorperazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- arsenic trioxide
prochlorperazine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.
- artemether/lumefantrine
prochlorperazine and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).
benzhydrocodone/acetaminophen and prochlorperazine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate - bromocriptine
prochlorperazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- buprenorphine subdermal implant
buprenorphine subdermal implant and prochlorperazine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- buprenorphine transdermal
buprenorphine transdermal and prochlorperazine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- cabergoline
prochlorperazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.
- calcium/magnesium/potassium/sodium oxybates
prochlorperazine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- chlorpromazine
chlorpromazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.
- clarithromycin
prochlorperazine and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug.
- degarelix
degarelix and prochlorperazine both decrease QTc interval. Avoid or Use Alternate Drug.
- dofetilide
prochlorperazine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.
- dopamine
prochlorperazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.
- dosulepin
prochlorperazine and dosulepin both increase QTc interval. Avoid or Use Alternate Drug.
- dronedarone
prochlorperazine and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.
- droperidol
prochlorperazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- epinephrine
epinephrine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.
- epinephrine racemic
epinephrine racemic and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin base
prochlorperazine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin ethylsuccinate
prochlorperazine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin lactobionate
prochlorperazine and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin stearate
prochlorperazine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.
- fentanyl
fentanyl, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.
- fentanyl intranasal
fentanyl intranasal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.
- fentanyl transdermal
fentanyl transdermal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.
- fentanyl transmucosal
fentanyl transmucosal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.
- fluconazole
prochlorperazine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.
- fluphenazine
fluphenazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.
- formoterol
prochlorperazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.
- haloperidol
prochlorperazine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.
- hydrocodone
hydrocodone, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).
- itraconazole
prochlorperazine and itraconazole both increase QTc interval. Avoid or Use Alternate Drug.
- ketoconazole
prochlorperazine and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.
- levodopa
prochlorperazine decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- levodopa inhaled
prochlorperazine decreases effects of levodopa inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Phenothiazine/1st generation antipsychotics inhibit dopamine D2 receptors in varying degrees.
- levoketoconazole
prochlorperazine and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.
- lisuride
prochlorperazine decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.
- lofepramine
prochlorperazine and lofepramine both increase QTc interval. Avoid or Use Alternate Drug.
- lumefantrine
prochlorperazine and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.
- methyl aminolevulinate
prochlorperazine, methyl aminolevulinate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.
- methyldopa
prochlorperazine decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.
- metoclopramide intranasal
prochlorperazine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
prochlorperazine increases toxicity of metoclopramide intranasal by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potential for additive effects, including increased frequency and severity of tardive dyskinesia, other extrapyramidal symptoms, and neuroleptic malignant syndrome. - moxifloxacin
prochlorperazine and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- nilotinib
prochlorperazine and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.
- octreotide
prochlorperazine and octreotide both increase QTc interval. Avoid or Use Alternate Drug.
- octreotide (Antidote)
prochlorperazine and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.
- olopatadine intranasal
prochlorperazine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- perphenazine
perphenazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.
- pramipexole
prochlorperazine decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.
- promazine
prochlorperazine and promazine both increase QTc interval. Avoid or Use Alternate Drug.
- promethazine
prochlorperazine and promethazine both increase QTc interval. Avoid or Use Alternate Drug.
- quinidine
quinidine, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive cardiac effects.
- ropinirole
prochlorperazine decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.
- safinamide
prochlorperazine decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms.
- saquinavir
saquinavir, prochlorperazine. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Increased risk of QT prolongation and cardiac arrhythmias.
- selinexor
selinexor, prochlorperazine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
- sodium oxybate
prochlorperazine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- tetrabenazine
tetrabenazine and prochlorperazine both decrease QTc interval. Avoid or Use Alternate Drug.
- thioridazine
prochlorperazine and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.
- tretinoin
prochlorperazine, tretinoin. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.
- tretinoin topical
prochlorperazine, tretinoin topical. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.
- trifluoperazine
prochlorperazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.
- yohimbe
yohimbe decreases effects of prochlorperazine by pharmacodynamic antagonism. Contraindicated.
- ziprasidone
prochlorperazine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.
Monitor Closely (303)
- abobotulinumtoxinA
abobotulinumtoxinA increases effects of prochlorperazine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.
- aclidinium
aclidinium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - acrivastine
acrivastine and prochlorperazine both increase sedation. Use Caution/Monitor.
- albiglutide
prochlorperazine, albiglutide. Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.
- albuterol
prochlorperazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- alfentanil
alfentanil and prochlorperazine both increase sedation. Use Caution/Monitor.
- alprazolam
alprazolam and prochlorperazine both increase sedation. Use Caution/Monitor.
- amifampridine
prochlorperazine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.
- amisulpride
prochlorperazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
- amitriptyline
prochlorperazine and amitriptyline both increase QTc interval. Use Caution/Monitor.
prochlorperazine and amitriptyline both increase sedation. Use Caution/Monitor. - amobarbital
amobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.
- amoxapine
prochlorperazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
prochlorperazine and amoxapine both increase QTc interval. Use Caution/Monitor.
prochlorperazine and amoxapine both increase sedation. Use Caution/Monitor. - anagrelide
anagrelide and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- anticholinergic/sedative combos
anticholinergic/sedative combos decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
anticholinergic/sedative combos decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - apomorphine
prochlorperazine and apomorphine both increase sedation. Use Caution/Monitor.
- arformoterol
prochlorperazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- aripiprazole
aripiprazole and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
aripiprazole and prochlorperazine both increase sedation. Use Caution/Monitor. - armodafinil
prochlorperazine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- artemether/lumefantrine
artemether/lumefantrine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- asenapine
asenapine and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
asenapine and prochlorperazine both increase sedation. Use Caution/Monitor. - asenapine transdermal
asenapine transdermal and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
asenapine transdermal and prochlorperazine both increase sedation. Use Caution/Monitor. - atracurium
atracurium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atracurium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - atropine
atropine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - atropine IV/IM
prochlorperazine increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
atropine IV/IM decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine IV/IM decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. - avapritinib
avapritinib and prochlorperazine both increase sedation. Use Caution/Monitor.
- azelastine
azelastine and prochlorperazine both increase sedation. Use Caution/Monitor.
- azithromycin
prochlorperazine and azithromycin both increase QTc interval. Use Caution/Monitor.
- baclofen
baclofen and prochlorperazine both increase sedation. Use Caution/Monitor.
- belladonna alkaloids
belladonna alkaloids decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
belladonna alkaloids decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - belladonna and opium
belladonna and opium and prochlorperazine both increase sedation. Use Caution/Monitor.
belladonna and opium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
belladonna and opium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - benperidol
benperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
benperidol and prochlorperazine both increase sedation. Use Caution/Monitor. - benzphetamine
prochlorperazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, benzphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - benztropine
prochlorperazine increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. .
- brexanolone
brexanolone, prochlorperazine. Either increases toxicity of the other by sedation. Use Caution/Monitor.
- brexpiprazole
brexpiprazole and prochlorperazine both increase sedation. Use Caution/Monitor.
- brimonidine
brimonidine and prochlorperazine both increase sedation. Use Caution/Monitor.
- brivaracetam
brivaracetam and prochlorperazine both increase sedation. Use Caution/Monitor.
- brompheniramine
brompheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.
- buprenorphine
buprenorphine and prochlorperazine both increase sedation. Use Caution/Monitor.
buprenorphine and prochlorperazine both decrease QTc interval. Use Caution/Monitor. - buprenorphine buccal
buprenorphine buccal and prochlorperazine both increase sedation. Use Caution/Monitor.
buprenorphine buccal and prochlorperazine both decrease QTc interval. Use Caution/Monitor. - buprenorphine subdermal implant
buprenorphine subdermal implant and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- buprenorphine transdermal
buprenorphine transdermal and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- buprenorphine, long-acting injection
prochlorperazine increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.
buprenorphine, long-acting injection and prochlorperazine both decrease QTc interval. Use Caution/Monitor. - bupropion
bupropion will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
prochlorperazine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible. - butabarbital
butabarbital and prochlorperazine both increase sedation. Use Caution/Monitor.
- butalbital
butalbital and prochlorperazine both increase sedation. Use Caution/Monitor.
- butorphanol
butorphanol and prochlorperazine both increase sedation. Use Caution/Monitor.
- caffeine
prochlorperazine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carbinoxamine
carbinoxamine and prochlorperazine both increase sedation. Use Caution/Monitor.
- carisoprodol
carisoprodol and prochlorperazine both increase sedation. Use Caution/Monitor.
- cenobamate
cenobamate, prochlorperazine. Either increases effects of the other by sedation. Use Caution/Monitor.
- chloral hydrate
chloral hydrate and prochlorperazine both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
chlordiazepoxide and prochlorperazine both increase sedation. Use Caution/Monitor.
- chlorpheniramine
chlorpheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.
- chlorpromazine
chlorpromazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
chlorpromazine and prochlorperazine both increase sedation. Use Caution/Monitor. - chlorzoxazone
chlorzoxazone and prochlorperazine both increase sedation. Use Caution/Monitor.
- cigarette smoking
cigarette smoking decreases levels of prochlorperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.
- cinnarizine
cinnarizine and prochlorperazine both increase sedation. Use Caution/Monitor.
- cisatracurium
cisatracurium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cisatracurium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - citalopram
citalopram and prochlorperazine both increase serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.
- clemastine
clemastine and prochlorperazine both increase sedation. Use Caution/Monitor.
- clobazam
prochlorperazine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
- clomipramine
prochlorperazine and clomipramine both increase QTc interval. Use Caution/Monitor.
prochlorperazine and clomipramine both increase sedation. Use Caution/Monitor. - clonazepam
clonazepam and prochlorperazine both increase sedation. Use Caution/Monitor.
- clonidine
clonidine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.
- clorazepate
clorazepate and prochlorperazine both increase sedation. Use Caution/Monitor.
- clozapine
clozapine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
clozapine and prochlorperazine both increase sedation. Use Caution/Monitor. - codeine
codeine and prochlorperazine both increase sedation. Use Caution/Monitor.
- cyclizine
cyclizine and prochlorperazine both increase sedation. Use Caution/Monitor.
cyclizine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclizine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - cyclobenzaprine
cyclobenzaprine and prochlorperazine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - cyproheptadine
cyproheptadine and prochlorperazine both increase sedation. Use Caution/Monitor.
- dantrolene
dantrolene and prochlorperazine both increase sedation. Use Caution/Monitor.
- daridorexant
prochlorperazine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- darifenacin
darifenacin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
darifenacin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - dasatinib
prochlorperazine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.
- deferoxamine
deferoxamine, prochlorperazine. Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Synergistic increase in neurological adverse effects.
- desflurane
desflurane and prochlorperazine both increase sedation. Use Caution/Monitor.
desflurane and prochlorperazine both decrease QTc interval. Use Caution/Monitor. - desipramine
prochlorperazine and desipramine both increase QTc interval. Use Caution/Monitor.
prochlorperazine and desipramine both increase sedation. Use Caution/Monitor. - desvenlafaxine
desvenlafaxine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
- deutetrabenazine
prochlorperazine and deutetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. The risk for parkinsonism, neuroleptic malignant syndrome, and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics.
deutetrabenazine and prochlorperazine both decrease QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation). - dexchlorpheniramine
dexchlorpheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.
- dexfenfluramine
prochlorperazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, dexfenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - dexmedetomidine
dexmedetomidine and prochlorperazine both increase sedation. Use Caution/Monitor.
- dexmethylphenidate
prochlorperazine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - dextroamphetamine
prochlorperazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, dextroamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - dextromoramide
dextromoramide and prochlorperazine both increase sedation. Use Caution/Monitor.
- diamorphine
diamorphine and prochlorperazine both increase sedation. Use Caution/Monitor.
- diazepam
diazepam and prochlorperazine both increase sedation. Use Caution/Monitor.
- dicyclomine
dicyclomine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
dicyclomine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - diethylpropion
prochlorperazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, diethylpropion. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - difelikefalin
difelikefalin and prochlorperazine both increase sedation. Use Caution/Monitor.
- difenoxin hcl
difenoxin hcl and prochlorperazine both increase sedation. Use Caution/Monitor.
- dimenhydrinate
dimenhydrinate and prochlorperazine both increase sedation. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and prochlorperazine both increase sedation. Use Caution/Monitor.
diphenhydramine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
diphenhydramine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - diphenoxylate hcl
diphenoxylate hcl and prochlorperazine both increase sedation. Use Caution/Monitor.
- dipipanone
dipipanone and prochlorperazine both increase sedation. Use Caution/Monitor.
- dobutamine
prochlorperazine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, dobutamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - dolasetron
prochlorperazine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.
- donepezil
donepezil and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- donepezil transdermal
donepezil transdermal, prochlorperazine. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.
- dopamine
prochlorperazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - dopexamine
prochlorperazine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dosulepin
prochlorperazine and dosulepin both increase sedation. Use Caution/Monitor.
- doxepin
prochlorperazine and doxepin both increase QTc interval. Use Caution/Monitor.
prochlorperazine and doxepin both increase sedation. Use Caution/Monitor. - doxylamine
doxylamine and prochlorperazine both increase sedation. Use Caution/Monitor.
- droperidol
droperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and prochlorperazine both increase sedation. Use Caution/Monitor. - efavirenz
efavirenz and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- eliglustat
eliglustat and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- encorafenib
encorafenib and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- entrectinib
entrectinib and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- ephedrine
prochlorperazine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, ephedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - epinephrine
prochlorperazine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, epinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.
prochlorperazine decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia. - epinephrine racemic
prochlorperazine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia. - eribulin
eribulin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- estazolam
estazolam and prochlorperazine both increase sedation. Use Caution/Monitor.
- ethanol
prochlorperazine and ethanol both increase sedation. Use Caution/Monitor.
- etomidate
etomidate and prochlorperazine both increase sedation. Use Caution/Monitor.
- fenfluramine
prochlorperazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, fenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - fesoterodine
fesoterodine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
fesoterodine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - fingolimod
fingolimod and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- flavoxate
flavoxate decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - flecainide
prochlorperazine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.
- fluoxetine
fluoxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
prochlorperazine and fluoxetine both increase QTc interval. Use Caution/Monitor. - fluphenazine
fluphenazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
fluphenazine and prochlorperazine both increase sedation. Use Caution/Monitor. - flurazepam
flurazepam and prochlorperazine both increase sedation. Use Caution/Monitor.
- fluvoxamine
fluvoxamine and prochlorperazine both increase QTc interval. Use Caution/Monitor.
- formoterol
prochlorperazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- foscarnet
prochlorperazine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.
- ganaxolone
prochlorperazine and ganaxolone both increase sedation. Use Caution/Monitor.
- gemifloxacin
gemifloxacin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- gilteritinib
gilteritinib and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- glycopyrrolate
prochlorperazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- glycopyrrolate inhaled
glycopyrrolate inhaled decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
glycopyrrolate inhaled decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - glycopyrronium tosylate topical
glycopyrronium tosylate topical, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.
- granisetron
granisetron and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- guanfacine
guanfacine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.
- haloperidol
haloperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
haloperidol and prochlorperazine both increase sedation. Use Caution/Monitor. - henbane
henbane decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
henbane decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of henbane by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - homatropine
homatropine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
homatropine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of homatropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - hydromorphone
hydromorphone and prochlorperazine both increase sedation. Use Caution/Monitor.
- hydroxyzine
hydroxyzine and prochlorperazine both increase sedation. Use Caution/Monitor.
hydroxyzine and prochlorperazine both decrease QTc interval. Use Caution/Monitor. - hyoscyamine
hyoscyamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of hyoscyamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - hyoscyamine spray
prochlorperazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. - iloperidone
iloperidone and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
prochlorperazine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.
iloperidone and prochlorperazine both increase sedation. Use Caution/Monitor. - imipramine
prochlorperazine and imipramine both increase QTc interval. Use Caution/Monitor.
prochlorperazine and imipramine both increase sedation. Use Caution/Monitor. - incobotulinumtoxinA
prochlorperazine, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.
- insulin degludec
prochlorperazine decreases effects of insulin degludec by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.
- insulin degludec/insulin aspart
prochlorperazine decreases effects of insulin degludec/insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.
- insulin inhaled
prochlorperazine decreases effects of insulin inhaled by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.
- ipratropium
ipratropium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
ipratropium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - isoflurane
isoflurane and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- isoproterenol
prochlorperazine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, isoproterenol. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - ketamine
ketamine and prochlorperazine both increase sedation. Use Caution/Monitor.
- ketotifen, ophthalmic
prochlorperazine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- lapatinib
prochlorperazine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.
- lasmiditan
lasmiditan, prochlorperazine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- lemborexant
lemborexant, prochlorperazine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- levalbuterol
prochlorperazine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- levofloxacin
prochlorperazine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- levorphanol
levorphanol and prochlorperazine both increase sedation. Use Caution/Monitor.
- liraglutide
prochlorperazine, liraglutide. Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.
- lisdexamfetamine
prochlorperazine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, lisdexamfetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - lithium
lithium, prochlorperazine. Other (see comment). Use Caution/Monitor. Comment: Risk of neurotoxicity. Multiple mechanisms involved.
lithium and prochlorperazine both decrease QTc interval. Use Caution/Monitor. - lofepramine
prochlorperazine and lofepramine both increase sedation. Use Caution/Monitor.
- lofexidine
prochlorperazine and lofexidine both increase sedation. Use Caution/Monitor.
- loprazolam
loprazolam and prochlorperazine both increase sedation. Use Caution/Monitor.
- lorazepam
lorazepam and prochlorperazine both increase sedation. Use Caution/Monitor.
- lormetazepam
lormetazepam and prochlorperazine both increase sedation. Use Caution/Monitor.
- loxapine
loxapine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
loxapine and prochlorperazine both increase sedation. Use Caution/Monitor. - loxapine inhaled
loxapine inhaled and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
loxapine inhaled and prochlorperazine both increase sedation. Use Caution/Monitor. - lumefantrine
lumefantrine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- lurasidone
lurasidone, prochlorperazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
- maprotiline
prochlorperazine and maprotiline both increase QTc interval. Use Caution/Monitor.
prochlorperazine and maprotiline both increase sedation. Use Caution/Monitor. - marijuana
prochlorperazine and marijuana both increase sedation. Use Caution/Monitor.
- meclizine
meclizine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - melatonin
prochlorperazine and melatonin both increase sedation. Use Caution/Monitor.
- meperidine
meperidine and prochlorperazine both increase sedation. Use Caution/Monitor.
- meprobamate
prochlorperazine and meprobamate both increase sedation. Use Caution/Monitor.
- metaproterenol
prochlorperazine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaxalone
metaxalone and prochlorperazine both increase sedation. Use Caution/Monitor.
- metformin
prochlorperazine decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor. Patient should be closely observed for loss of blood glucose control; when drugs are withdrawn from a patient receiving metformin, patient should be observed closely for hypoglycemia.
- methadone
prochlorperazine and methadone both increase QTc interval. Modify Therapy/Monitor Closely.
methadone and prochlorperazine both increase sedation. Use Caution/Monitor. - methamphetamine
prochlorperazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, methamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - methocarbamol
methocarbamol and prochlorperazine both increase sedation. Use Caution/Monitor.
- methoxsalen
methoxsalen, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects.
- methscopolamine
methscopolamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
methscopolamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of methscopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - methylenedioxymethamphetamine
prochlorperazine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, methylenedioxymethamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - methylphenidate
prochlorperazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.
- metoclopramide
prochlorperazine and metoclopramide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
- midazolam
midazolam and prochlorperazine both increase sedation. Use Caution/Monitor.
- midazolam intranasal
midazolam intranasal, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- midodrine
prochlorperazine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, midodrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - mirtazapine
prochlorperazine and mirtazapine both increase sedation. Use Caution/Monitor.
mirtazapine and prochlorperazine both decrease QTc interval. Use Caution/Monitor. - modafinil
prochlorperazine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- morphine
morphine and prochlorperazine both increase sedation. Use Caution/Monitor.
- motherwort
prochlorperazine and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
prochlorperazine and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
prochlorperazine and nabilone both increase sedation. Use Caution/Monitor.
- nalbuphine
nalbuphine and prochlorperazine both increase sedation. Use Caution/Monitor.
- norepinephrine
prochlorperazine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, norepinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - nortriptyline
prochlorperazine and nortriptyline both increase QTc interval. Use Caution/Monitor.
prochlorperazine and nortriptyline both increase sedation. Use Caution/Monitor. - ofloxacin
prochlorperazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- olanzapine
olanzapine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
olanzapine and prochlorperazine both increase sedation. Use Caution/Monitor.
olanzapine and prochlorperazine both decrease QTc interval. Use Caution/Monitor. - oliceridine
oliceridine, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).
- onabotulinumtoxinA
onabotulinumtoxinA decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
onabotulinumtoxinA decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - opium tincture
opium tincture and prochlorperazine both increase sedation. Use Caution/Monitor.
- orphenadrine
orphenadrine and prochlorperazine both increase sedation. Use Caution/Monitor.
- oxaliplatin
oxaliplatin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- oxazepam
oxazepam and prochlorperazine both increase sedation. Use Caution/Monitor.
- oxybutynin
oxybutynin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
oxybutynin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - oxybutynin topical
oxybutynin topical decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
oxybutynin topical decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - oxybutynin transdermal
oxybutynin transdermal decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
oxybutynin transdermal decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - oxycodone
oxycodone and prochlorperazine both increase sedation. Use Caution/Monitor.
- oxymorphone
oxymorphone and prochlorperazine both increase sedation. Use Caution/Monitor.
- paliperidone
paliperidone and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
prochlorperazine and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.
paliperidone and prochlorperazine both increase sedation. Use Caution/Monitor. - pancuronium
pancuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
pancuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of pancuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - papaveretum
papaveretum and prochlorperazine both increase sedation. Use Caution/Monitor.
- papaverine
prochlorperazine and papaverine both increase sedation. Use Caution/Monitor.
- paroxetine
paroxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
prochlorperazine and paroxetine both increase QTc interval. Use Caution/Monitor. - pazopanib
prochlorperazine and pazopanib both increase QTc interval. Use Caution/Monitor.
- pentazocine
pentazocine and prochlorperazine both increase sedation. Use Caution/Monitor.
- pentobarbital
pentobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.
- perphenazine
perphenazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
perphenazine and prochlorperazine both increase sedation. Use Caution/Monitor. - phendimetrazine
prochlorperazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, phendimetrazine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - phenobarbital
phenobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.
- phentermine
prochlorperazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, phentermine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - phenylephrine
prochlorperazine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, phenylephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - phenylephrine PO
prochlorperazine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
prochlorperazine, phenylephrine PO. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - pholcodine
prochlorperazine and pholcodine both increase sedation. Use Caution/Monitor.
- pimozide
pimozide and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
pimozide and prochlorperazine both increase sedation. Use Caution/Monitor. - pirbuterol
prochlorperazine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- porfimer
prochlorperazine, porfimer. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced photosensitivity.
- posaconazole
prochlorperazine and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- pralidoxime
pralidoxime decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
pralidoxime decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of pralidoxime by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - primaquine
primaquine and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- primidone
primidone and prochlorperazine both increase sedation. Use Caution/Monitor.
- procarbazine
procarbazine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Excessive sedation.
- promethazine
prochlorperazine and promethazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
promethazine and prochlorperazine both increase sedation. Use Caution/Monitor. - propafenone
propafenone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- propantheline
propantheline decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
propantheline decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - propofol
propofol and prochlorperazine both increase sedation. Use Caution/Monitor.
- propylhexedrine
prochlorperazine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, propylhexedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - protriptyline
prochlorperazine and protriptyline both increase QTc interval. Use Caution/Monitor.
prochlorperazine and protriptyline both increase sedation. Use Caution/Monitor. - pseudoephedrine
prochlorperazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.
- quazepam
quazepam and prochlorperazine both increase sedation. Use Caution/Monitor.
- quetiapine
prochlorperazine and quetiapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
prochlorperazine and quetiapine both increase sedation. Use Caution/Monitor. - quinidine
quinidine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- ramelteon
prochlorperazine and ramelteon both increase sedation. Use Caution/Monitor.
- ranolazine
prochlorperazine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.
- rapacuronium
rapacuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
rapacuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of rapacuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - rimabotulinumtoxinB
prochlorperazine, rimabotulinumtoxinB. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Anticholinergics may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.
- risperidone
prochlorperazine and risperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
prochlorperazine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.
prochlorperazine and risperidone both increase sedation. Use Caution/Monitor. - rocuronium
rocuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
rocuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of rocuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - salmeterol
prochlorperazine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- scopolamine
scopolamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
scopolamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of scopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - scullcap
prochlorperazine and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
secobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.
- serdexmethylphenidate/dexmethylphenidate
prochlorperazine, serdexmethylphenidate/dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.
- sertraline
sertraline and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- sevoflurane
sevoflurane and prochlorperazine both increase sedation. Use Caution/Monitor.
sevoflurane and prochlorperazine both decrease QTc interval. Use Caution/Monitor. - shepherd's purse
prochlorperazine and shepherd's purse both increase sedation. Use Caution/Monitor.
- siponimod
siponimod and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- smoking
smoking decreases levels of prochlorperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.
- solifenacin
solifenacin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
solifenacin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
solifenacin and prochlorperazine both decrease QTc interval. Use Caution/Monitor. - stiripentol
stiripentol, prochlorperazine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.
- sufentanil
sufentanil and prochlorperazine both increase sedation. Use Caution/Monitor.
- sulfamethoxazole
prochlorperazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- sunitinib
sunitinib and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- tacrolimus
tacrolimus and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- tapentadol
tapentadol and prochlorperazine both increase sedation. Use Caution/Monitor.
- teduglutide
teduglutide increases levels of prochlorperazine by Other (see comment). Use Caution/Monitor. Comment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.
- telavancin
prochlorperazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- temazepam
temazepam and prochlorperazine both increase sedation. Use Caution/Monitor.
- terbutaline
prochlorperazine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- tetrabenazine
prochlorperazine and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
- thioridazine
prochlorperazine and thioridazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
prochlorperazine and thioridazine both increase sedation. Use Caution/Monitor. - thiothixene
prochlorperazine and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
prochlorperazine and thiothixene both increase sedation. Use Caution/Monitor. - tiotropium
tiotropium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
tiotropium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - tobacco use
tobacco use decreases levels of prochlorperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.
- tolterodine
tolterodine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
tolterodine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of tolterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - topiramate
prochlorperazine and topiramate both increase sedation. Modify Therapy/Monitor Closely.
- tramadol
tramadol and prochlorperazine both increase sedation. Use Caution/Monitor.
- trazodone
prochlorperazine and trazodone both increase QTc interval. Use Caution/Monitor.
prochlorperazine and trazodone both increase sedation. Use Caution/Monitor. - triazolam
triazolam and prochlorperazine both increase sedation. Use Caution/Monitor.
- triclofos
triclofos and prochlorperazine both increase sedation. Use Caution/Monitor.
- trifluoperazine
prochlorperazine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
prochlorperazine and trifluoperazine both increase sedation. Use Caution/Monitor. - trihexyphenidyl
trihexyphenidyl decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive anticholinergic effects. - trimethoprim
prochlorperazine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.
- trimipramine
prochlorperazine and trimipramine both increase QTc interval. Use Caution/Monitor.
prochlorperazine and trimipramine both increase sedation. Use Caution/Monitor. - triprolidine
triprolidine and prochlorperazine both increase sedation. Use Caution/Monitor.
- tropisetron
prochlorperazine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.
- trospium chloride
trospium chloride decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
trospium chloride decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of trospium chloride by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - valbenazine
valbenazine and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- vecuronium
vecuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
vecuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - venlafaxine
venlafaxine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
prochlorperazine and venlafaxine both increase QTc interval. Use Caution/Monitor. - voriconazole
prochlorperazine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- vorinostat
vorinostat and prochlorperazine both decrease QTc interval. Use Caution/Monitor.
- xylometazoline
prochlorperazine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, xylometazoline. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - yohimbine
prochlorperazine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
prochlorperazine, yohimbine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. - ziconotide
prochlorperazine and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
prochlorperazine and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
prochlorperazine and ziprasidone both increase sedation. Use Caution/Monitor. - zolpidem
prochlorperazine will increase the level or effect of zolpidem by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Additive effect of decreased alertness and psychomotor performance
- zotepine
prochlorperazine and zotepine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
prochlorperazine and zotepine both increase sedation. Use Caution/Monitor.
Minor (60)
- amiodarone
amiodarone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- amitriptyline
amitriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
amitriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - amoxapine
amoxapine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
amoxapine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - asenapine
asenapine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- atropine
prochlorperazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.
- atropine IV/IM
prochlorperazine increases toxicity of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.
- benazepril
prochlorperazine increases effects of benazepril by unspecified interaction mechanism. Minor/Significance Unknown. Enhanced hypotensive effects.
- brimonidine
brimonidine increases effects of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- captopril
prochlorperazine increases effects of captopril by unspecified interaction mechanism. Minor/Significance Unknown.
- celecoxib
celecoxib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- chasteberry
chasteberry decreases effects of prochlorperazine by pharmacodynamic antagonism. Minor/Significance Unknown. (Theoretical interaction).
- chloroquine
chloroquine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
chloroquine increases levels of prochlorperazine by decreasing metabolism. Minor/Significance Unknown. - cimetidine
cimetidine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- clomipramine
clomipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
clomipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - darifenacin
darifenacin will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- desipramine
desipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
desipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - diphenhydramine
diphenhydramine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- doxepin
doxepin, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
doxepin, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - dronedarone
dronedarone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- duloxetine
duloxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- enalapril
prochlorperazine increases effects of enalapril by unspecified interaction mechanism. Minor/Significance Unknown.
- ethanol
ethanol, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.
- eucalyptus
prochlorperazine and eucalyptus both increase sedation. Minor/Significance Unknown.
- fosinopril
prochlorperazine increases effects of fosinopril by unspecified interaction mechanism. Minor/Significance Unknown.
- glycopyrrolate
prochlorperazine increases toxicity of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.
- glycopyrrolate inhaled
prochlorperazine increases toxicity of glycopyrrolate inhaled by unknown mechanism. Minor/Significance Unknown.
- haloperidol
haloperidol will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- imatinib
imatinib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- imidapril
prochlorperazine increases effects of imidapril by unspecified interaction mechanism. Minor/Significance Unknown.
- imipramine
imipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
imipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - lisinopril
prochlorperazine increases effects of lisinopril by unspecified interaction mechanism. Minor/Significance Unknown.
- lofepramine
lofepramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
lofepramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - maprotiline
maprotiline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
maprotiline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - maraviroc
maraviroc will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- marijuana
marijuana will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- metyrapone
prochlorperazine decreases effects of metyrapone by unspecified interaction mechanism. Minor/Significance Unknown.
- metyrosine
metyrosine increases toxicity of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased extrapyramidal symptoms.
- moexipril
prochlorperazine increases effects of moexipril by unspecified interaction mechanism. Minor/Significance Unknown.
- nilotinib
nilotinib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- nortriptyline
nortriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
nortriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - oxybutynin
oxybutynin increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.
- oxybutynin topical
oxybutynin topical increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.
- oxybutynin transdermal
oxybutynin transdermal increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.
- parecoxib
parecoxib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- perindopril
prochlorperazine increases effects of perindopril by unspecified interaction mechanism. Minor/Significance Unknown.
- perphenazine
perphenazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- protriptyline
protriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
protriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - pyrimethamine
pyrimethamine increases levels of prochlorperazine by decreasing metabolism. Minor/Significance Unknown.
- quinacrine
quinacrine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- quinapril
prochlorperazine increases effects of quinapril by unspecified interaction mechanism. Minor/Significance Unknown.
- ramipril
prochlorperazine increases effects of ramipril by unspecified interaction mechanism. Minor/Significance Unknown.
- ranolazine
ranolazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- ritonavir
ritonavir will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- sage
prochlorperazine and sage both increase sedation. Minor/Significance Unknown.
- sertraline
sertraline will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- thioridazine
thioridazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- tipranavir
tipranavir will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
- trandolapril
prochlorperazine increases effects of trandolapril by unspecified interaction mechanism. Minor/Significance Unknown.
- trazodone
trazodone, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
trazodone, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. - trimipramine
trimipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
trimipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
Adverse Effects
<1%
Insomnia
Restlessness (immediate restlessness or agitation may be treated with diphenhydramine 25 mg IV push)
Dizziness
Anxiety
Euphoria
Agitation
Depression
Weakness
Headache
Cerebral edema
Poikilothermia
Orthostatic hypotension (after IM injection)
Tachycardia
ECG changes
Anorexia
Dyspepsia
Constipation
Diarrhea
Ileus
Blood dyscrasia
Galactorrhea
Gynecomastia
Ejaculatory disorder
Lens opacities (with prolonged use)
Photosensitivity
Pruritus
Frequency Not Defined
Akathisia
Sedation
Anticholinergic effects
Weight gain
Oligomenorrhea or amenorrhea
Erectile dysfunction
Extrapyramidal symptoms (muscle stiffness, dystonia, parkinsonism, tardive dyskinesia)
Neuroleptic malignant syndrome (infrequent but serious)
Seizure
Decreased gag reflex
Confusion
Hypotension
Hypertension
Leukopenia
Agranulocytosis
Cholestatic jaundice
Photosensitivity reaction
Priapism
Hepatotoxicity
Warnings
Black Box Warnings
Patients with dementia-related psychosis who are treated with antipsychotic drugs are at an increased risk of death, as shown in short-term controlled trials; the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature
This drug is not approved for treatment of patients with dementia-related psychosis
Contraindications
Documented hypersensitivity to phenothiazines
Coma, severe CNS depression, concurrent use of large amounts of CNS depressants, poorly controlled seizure disorder, subcortical brain damage
Postoperative management of nausea/vomiting following pediatric surgery
Children <2 years or weighing <9 kg
Cautions
Avoid using in children with suspected Reye syndrome
Use caution in evere hypertension, severe cardiovascular disease
Use with caution in glaucoma, prostatic hypertrophy, stenosing peptic ulcer disease, history of neuroleptic malignant syndrome, Parkinson disease, hypocalcemia, renal/hepatic impairment, history of severe reactions to insulin or electroconvulsive therapy, history of seizures, asthma, respiratory tract infections, cardiovascular disease, myelosuppression
Blood dyscrasias including neutropenia, agranulocytosis, and leukopenia reported with use; discontinue therapy at first sign of blood dyscrasias
Risk of extrapyramidal symptoms, neuroleptic malignant syndrome, hypotension (may be particularly severe in patients with pheochromocytoma or mitral insufficiency)
Esophageal dysmotility/aspiration may occur; use with caution in patients at risk of pneumonia
Depresses hypothalamic thermoregulatory mechanism; exposure to extreme temperatures may cause hypo- or hyperthermia
May alter cardiac conduction; life-threatening arrhythmias reported with therapeutic doses
May cause anticholinergic effects (constipation, xerostomia, urinary retention, blurred vision); use caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, visual problems
May cause pigmentary retinopathy and lenticular and corneal deposits, especially in prolonged therapy
May cause sedation and impair ability to perform tasks which require mental alertness, including operating heavy machinery
Use associated with increased prolactin levels
In case of severe hypotension, use norepinephrine or phenylepinephrine; do not use epinephrine or dopamine
Do not crush extended-release product
Avoid SC administration (may cause irritation)
Antiemetic effect may obscure toxicity of chemotherapeutic drugs
Use may be associated with neuroleptic malignant syndrome; monitor muscle rigidity, mental status changes, fever, autonomic instability
May need anticholinergic antiparkinsonian agent to counter extrapyramidal symptoms
May impair core body temperature regulation
FDA warning regarding off-label use for dementia in elderly
Pregnancy & Lactation
Pregnancy category: C
Lactation: Phenothiazines may be excreted in breast milk; do not nurse
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Antiemetic: Antidopaminergic effect, blocking dopamine receptors in the brain, blocking vagus nerve in GI tract
Antipsychotic: Blocking mesolimbic dopamine receptors, and blocking alpha-adrenergic receptors (D1 and D2) in brain
Absorption
Bioavailability: 12.5%
Onset: 10-20 min (IM); 30-40 min (PO); 60 min (PR)
Duration: 3-4 hr (PO); 3-12hr (PR); extended-release, 10-12 hr
Distribution
Vd: 1400-1548 L
Metabolism
Metabolized by liver
Metabolites: N-desmethyl prochlorperazine (active)
Elimination
Half-life: 6.8-9 hr (PO); 6-10 hr (IV)
Dialyzable: No
Excretion: Feces (primarily)
Administration
IV Compatibilities
Solution: Compatible with most common solvents
Additive: Amikacin, ascorbic acid injection, dexamethasone, dimenhydrinate, erythromycin, ethacrynate, lidocaine, nafcillin, penicillin G potassium (incompatible at higher concentrations), sodium bicarbonate, vitamins B and C
Syringe (partial list): Atropine, chlorpromazine, cimetidine, diphenhydramine, fentanyl, glycopyrrolate, hydroxyzine, meperidine, metoclopramide, morphine sulfate (incompatible if phenol present)(?)
Y-site (partial list): Calcium gluconate, cisplatin, cladribine, clarithromycin, cyclophosphamide, cytarabine, docetaxel, doxorubicin, doxorubicin liposomal, heparin, linezolid, melphalan, methotrexate, potassium chloride, propofol, teniposide, thiotepa, topotecan, vitamins B and C
IV Incompatibilities
Additive: Aminophylline, amphotericin B, ampicillin, calcium gluconate(?), chloramphenicol, chlorothiazide, floxacillin, furosemide, hydrocortisone, methohexital, penicillin G sodium, phenobarbital, thiopental
Syringe: Dimenhydrinate, hydromorphone(?), ketorolac, midazolam, morphine tartate, pentobarbital, thiopental
Y-site: Aldesleukin, allopurinol, amifostine, amphotericin B, aztreonam, bivalirudin, cefepime, etoposide phosphate, fenoldopam, filgrastim, fludarabine, foscarnet, gemcitabine, piperacillin/tazobactam
IV Administration
Avoid bolus
IV push rate should not exceed 5 mg/min
For infusion, dilute 20 mg in 1 L of compatible solution; may infuse over 30 minutes
Storage
Store at room temperature, and protect from light
Solution is clear or slightly yellow
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
prochlorperazine edisylate injection - | 5 mg/mL vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() | |
prochlorperazine edisylate injection - | 5 mg/mL vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() | |
prochlorperazine edisylate injection - | 10 mg/2 mL (5 mg/mL) vial | ![]() |
Copyright © 2010 First DataBank, Inc.
Patient Handout
prochlorperazine edisylate injection
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.